Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.62 |
| ▸ | DRD1 | P21728 | 3/20 | 0.53 |
| ▸ | PTPRCAP | Q14761 | 2/20 | 0.53 |
| ▸ | DRD2 | P14416 | 4/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL6905306 | 0.99 | HTR2C (0.61) | HTR2CDRD1PTPRCAPDRD2HTR2A | |
| SCHEMBL3160390 | 0.90 | HTR2C (0.65) | HTR2CDRD1PTPRCAPDRD2HTR2A | |
| SCHEMBL3178138 | 0.81 | HTR2C (0.58) | HTR2CDRD1PTPRCAPDRD2HTR2A | |
| SCHEMBL6237859 | 0.80 | HTR2C (0.70) | HTR2CDRD1PTPRCAPDRD2HTR2A | |
| SCHEMBL3174699 | 0.78 | HTR2C (0.68) | HTR2CDRD1PTPRCAPDRD2HTR2A | |
| SCHEMBL3176273 | 0.75 | HTR2C (0.63) | HTR2CDRD1PTPRCAPDRD2HTR2A | |
| SCHEMBL276490 | 0.75 | DRD2 (0.60) | HTR2CDRD1DRD2HTR2ADRD3 | |
| SCHEMBL14782159 | 0.74 | HTR2C (0.58) | HTR2CDRD1PTPRCAPDRD2HTR2A | |
| SCHEMBL1345733 | 0.73 | HTR1A (0.63) | HTR2CDRD1PTPRCAPDRD2HTR2A | |
| Bromide SCHEMBL7111710 | 0.73 | HTR2C (0.57) | HTR2CDRD1PTPRCAPDRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010019856-A1 | METHODS AND KITS FOR TREATINGS STROKE AND OTHER NEUROLOGICAL CONDITIONS | THE MCLEAN HOSPITAL CORPORATION (US) | 2010-02-18 | — | — | WO | claimed |
| EP-4714407-A2 | DEVICES TO PROVIDE HANDS FREE SCLERAL DEPRESSION DURING OPHTHALMIC PROCEDURES | Alcon Inc. (CH) | 2026-03-25 | — | — | EP | disclosed |
| EP-3157408-B1 | DEVICES TO PROVIDE HANDS FREE SCLERAL DEPRESSION DURING OPHTHALMIC PROCEDURES | ALCON INC (CH) | 2026-03-25 | — | — | EP | disclosed |
| US-20250057694-A1 | DEVICES AND METHODS TO PROVIDE HANDS FREE SCLERAL DEPRESSION AND ILLUMINATION DURING OPHTHALMIC PROCEDURES | Ganihand, LLC (US) | 2025-02-20 | — | — | US | disclosed |
| CN-112040929-B | Improved pharmaceutical formulation | 辉凌公司 | 2024-08-30 | — | — | CN | disclosed |
| CN-114846019-A | Co-crystals of steroids and secosteroids and compositions containing same | 晶体工程智能研究中心公司 | 2022-08-02 | — | — | CN | disclosed |
| US-11266395-B2 | Devices and methods to provide hands free scleral depression during ophthalmic procedures | Ganihand, LLC (US) | 2022-03-08 | — | — | US | disclosed |
| CN-112040929-A | Improved pharmaceutical formulations | 辉凌公司 | 2020-12-04 | — | — | CN | disclosed |
| WO-2020150146-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIAC INJURY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-07-23 | — | — | WO | disclosed |
| WO-2020150147-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR CONDITIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20100081651-A1 | R(-)-11-HYDROXYAPORPHINE DERIVATIVES AND USES THEREOF | THE MCLEAN HOSPITAL CORPORATION (US) | 2010-04-01 | — | — | US | disclosed |
| WO-2010019856-A1 | METHODS AND KITS FOR TREATINGS STROKE AND OTHER NEUROLOGICAL CONDITIONS | THE MCLEAN HOSPITAL CORPORATION (US) | 2010-02-18 | — | — | WO | disclosed |
| US-7648995-B2 | R(—)-11-hydroxyaporphine derivatives and uses thereof | THE MCLEAN HOSPITAL CORPORATION (US) | 2010-01-19 | — | — | US | disclosed |
| US-20060040900-A1 | R(-)-11-hydroxyaporphine derivatives and uses thereof | MCLEAN HOSPITAL CORPORATION, THE | 2006-02-23 | — | — | US | disclosed |
| WO-2005110285-A2 | VARIABLE WALL ENDOVASCULAR STENT | GMP/CARDIAC CARE, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005079301-A2 | VENA CAVA RAIL FILTER | GMP CARDIAC CARE, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| EP-1494664-A2 | COMBINATIONS OF COX-2 INHIBITORS AND OTHER AGENTS FOR THE TREATMENT OF PARKINSON'S DISEASE | Pharmacia Corporation (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20040106975-A1 | Rail stent | GMP/CARDIAC CARE, INC. | 2004-06-03 | — | — | US | disclosed |
| US-20040034083-A1 | Combination therapy for the treatment of Parkinson's disease with cyclooxygenase-2 (COX2) inhibitor(s) | PHARMACIA CORPORATION | 2004-02-19 | — | — | US | disclosed |
| WO-2003088958-A2 | COMBINATIONS OF COX-2 INHIBITORS AND OTHER AGENTS FOR THE TREATMENT OF PARKINSON’S DISEASE | PHARMACIA CORPORATION (US) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040900-A1 | R(-)-11-hydroxyaporphine derivatives and uses thereof | SNCA, HTR5A, PARK7 | HTR2C 10/4885DRD1 34/4885PTPRCAP 2541/4885 |
| US-20100081651-A1 | R(-)-11-HYDROXYAPORPHINE DERIVATIVES AND USES THEREOF | SNCA, HTR5A, HTR3A | HTR2C 9/4885DRD1 36/4885PTPRCAP 2620/4885 |
| US-20040034083-A1 | Combination therapy for the treatment of Parkinson's disease with cyclooxygenase-2 (COX2) inhibitor(s) | PTGES2, PTGS2, PTGER2 | HTR2C 220/4885DRD1 1842/4885PTPRCAP 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.